Ixekizumab
Küçük Resim Yok
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Galenos Publ House
Erişim Hakkı
info:eu-repo/semantics/openAccess
Özet
Ixekizumab is a human immunoglobulin G4 monoclonal antibody targeting interleukin-17A. Clinical trials have reported that 82-84% of the patients using ixekizumab achieved a PASI90 response at week 12 and 85% at week 60. It has been found effective in chronic plaque psoriasis as well as genital, hairy skin, nail, and generalized pustular psoriasis in adults. It has been approved by the FDA for use in moderate psoriasis in patients aged between 6 and 18 years.
Açıklama
Anahtar Kelimeler
Anti-IL-17, ixekizumab, psoriasis, Severe Plaque Psoriasis, Moderate, Efficacy, Phase-3, Trials
Kaynak
Turkderm-Turkish Archives Of Dermatology And Venerology
WoS Q Değeri
N/A
Scopus Q Değeri
Cilt
56
